Entry

D08699            Mixture   Drug

Name

Salmeterol xinafoate and fluticasone propionate;
Adoair diskus (TN);
Aerivio Spiromax (TN)

Product

ADVAIR (A-S Medication Solutions), ADVAIR (GlaxoSmithKline LLC), AIRDUO RESPICLICK (Teva Respiratory), AIRDUO DIGIHALER (Teva Respiratory), ADVAIR HFA (GlaxoSmithKline LLC)

Generic

FLUTICASONE PROPIONATE AND SALMETEROL (A-S Medication Solutions), FLUTICASONE PROPIONATE AND SALMETEROL (A-S Medication Solutions), FLUTICASONE PROPIONATE AND SALMETEROL (A-S Medication Solutions), FLUTICASONE PROPIONATE AND SALMETEROL (A-S Medication Solutions), FLUTICASONE PROPIONATE AND SALMETEROL (Bryant Ranch Prepack), FLUTICASONE PROPIONATE AND SALMETEROL (Bryant Ranch Prepack), FLUTICASONE PROPIONATE AND SALMETEROL (Bryant Ranch Prepack), FLUTICASONE PROPIONATE AND SALMETEROL (Hikma Pharmaceuticals USA), WIXELA INHUB (Mylan Pharmaceuticals), FLUTICASONE PROPIONATE AND SALMETEROL (Prasco Laboratories), FLUTICASONE PROPIONATE AND SALMETEROL (Proficient Rx LP), WIXELA INHUB (REMEDYREPACK), FLUTICASONE PROPIONATE AND SALMETEROL (Teva Pharmaceuticals USA), FLUTICASONE PROPIONATE AND SALMETEROL (Teva Pharmaceuticals USA)

Component

Salmeterol xinafoate [DR:D00687], Fluticasone propionate [DR:D01708]

Class

Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate

Remark

Therapeutic category:

2290

ATC code:

R01AD58 R03AK06

Product:

D08699<JP/US>

Efficacy

Antiasthmatic

Disease

Asthma [DS:H00079]
Chronic obstructive pulmonary disease [DS:H01714]

Metabolism

Enzyme: CYP3A4 [HSA:1576]

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
  R01 NASAL PREPARATIONS
   R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
    R01AD Corticosteroids
     R01AD58 Fluticasone, combinations
      D08699  Salmeterol xinafoate and fluticasone propionate <JP/US>
  R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
   R03A ADRENERGICS, INHALANTS
    R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
     R03AK06 Salmeterol and fluticasone
      D08699  Salmeterol xinafoate and fluticasone propionate <JP/US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
  Bronchodilator Combinations
   Fluticasone Propionate/ Salmeterol
    D08699  Salmeterol xinafoate and fluticasone propionate
Therapeutic category of drugs in Japan [BR:br08301]
2  Agents affecting individual organs
  22  Respiratory organ agents
   229  Miscellaneous
    2290  Miscellaneous
     D08699  Salmeterol xinafoate and fluticasone propionate
Drug groups [BR:br08330]
Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D08699  Salmeterol xinafoate and fluticasone propionate
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D08699
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D08699

Other DBs

PubChem:

96025382